sur GBC Kapital GmbH
GBC Kapital Supports Marinomed's Capital Increase Success
Marinomed Biotech AG has completed a significant capital increase, supported by GBC Kapital GmbH. This success marks a crucial financial milestone for the listed biotechnology company headquartered in the German-speaking region. Marinomed, traded under ISIN: ATMARINOMED6 and WKN: A2N9MM, aims to use this financial bolster to advance its strategic and operational development efforts, especially for its lead products Budesolv and Tacrosolv.
This move increases Marinomed's financial flexibility and underscores investor confidence in its technology platform and future growth. GBC Kapital's role in this transaction follows its successful support in the December 2025 full placement of A.H.T. Syngas Technology N.V.'s convertible bond, showing their continued prowess in customized financing solutions for companies.
The newly issued shares will soon commence trading on the Vienna Stock Exchange, subject to standard formalities.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GBC Kapital GmbH